Company Information from ICIS

Novartis is a pharmaceuticals, consumer health, generics, eye-care, and animal health company. Its main business units are Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health.

The Pharmaceuticals business remains its biggest and most profitable business. Strong growth was shown by the cardiovascular and oncology franchises. However, it sees its main challenge as ‘keeping a sharp eye on the market evolution’.

Novartis has a strategy of consistent investment in R&D, enabling it to bring to market innovative and differentiated products that offer patients clear therapeutic benefits. It is expanding its generics business to provide affordable treatment options following patent expiries and it is developing promising new growth platforms such as vaccines to reduce healthcare costs through disease prevention.

Download the The ICIS Top 100 Chemical Companies listing here

Key Personnel

Chairman and board member: Daniel Vasella
Vice chairman and lead director: Ulrich Lehner
Vice chairman: Hans-Joerg Rudloff
Board member: William Brody
Board member: Srikant Datar
Board member: Ann Fudge
Board member: Alexandre Jetzer
Board member: Pierre Landolt
Board member: Andreas von Planta
Board member: Wendelin Wiedeking
Board member: Marjorie Yang
Board member: Rolf Zinkernagel
Corporate secretary: Monika Matti

Novartis International AG
CH-4002 Basel

Tel: +41 61 324 1111
Fax: +41 61 324 8001


ICIS Top 100 Chemical Companies


The ICIS Top 100 Chemical Companies 2015 listing highlights the top players in the global chemical industry.

Most chemical companies found it difficult to generate top line and profit growth in 2015 following a strong performance in 2014. 

ICIS Top 100 Chemical Distributors 2015

ICIS Top 100 Chemical Distributors 2014

ICIS is proud to present the ICIS Top 100 Chemical Distributors. This feature, now in its fifth year is published annually in ICIS Chemical Business, the weekly magazine for the global chemical industry.